ArticleRheumatology international2025
Preferences regarding technology to unobtrusively monitor symptoms in rheumatoid arthritis: a qualitative study using focus group discussions.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Digital tools can be used for both self-tracking and telemonitoring of symptoms of rheumatoid arthritis. However, long-term monitoring can be a significant burden on patients, hindering implementation. The objective of this study is to understand patient preferences and barriers regarding long-term symptom monitoring. Five focus groups with 20 people with rheumatoid arthritis (RA) and 14 healthcare professionals were organised. Topics included motivations to monitor, motivators and barriers, willingness to put effort into monitoring, data collection, and privacy concerns. People with RA are interested in self-tracking to support self-management, and in optimizing hospital visits through telemonitoring. Monitoring has to be personalized, with a wearable and affordable device, to monitor a variety of symptoms. People are willing to invest up to 3 months to personalize settings. After that, long-term monitoring should be unobtrusive, not requiring active participation. Data should be processed and presented with clear feedback. Data should also be shared with healthcare professionals to improve disease management and to optimize hospital visits. Medical professionals see benefits as patients become better informed. Telemonitoring is perceived especially relevant if information on disease activity and medication side-effects can be obtained. People with RA see benefits for long-term monitoring, both with regard to self-tracking and telemonitoring. Even though they are willing to invest initial effort, for the long-term monitoring they prefer more unobtrusive types of monitoring. Similarly, medical professionals see benefits in only seeing patients when needed, however; they fear an overload on information which could raise the workload even further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.